Jill Hanson, MD
Allergy & Immunology · Colorado Springs, CONPI 1366763807
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), consulting fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AstraZeneca at 42.4% of the total.
Across 454 payments — averaging $34.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Sanofi$3K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$843
- AbbVie$803
- Regeneron Healthcare Solutions, Inc.$573
- plus $2K from 24 others
What the payments were for
- Consulting fees$6,42741%
- Food & beverage$8,84657%
- Education$2161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $6,575 |
| Sanofi | 83 | $3,418 |
| GSK | 87 | $1,316 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $843 |
| AbbVie | 42 | $803 |
| Regeneron Healthcare Solutions, Inc. | 39 | $573 |
| Novartis | 22 | $421 |
| Genentech USA, Inc. | 12 | $229 |
| Sanofi-aventis U.S. LLC | 6 | $226 |
| Inspire Medical Systems, Inc. | 3 | $146 |
| Amgen | 4 | $135 |
| Grifols USA, LLC | 6 | $128 |
| CSL Behring | 5 | $110 |
| Kaleo, Inc. | 7 | $109 |
| Pfizer | 3 | $68 |
| Boehringer Ingelheim | 4 | $50 |
| Blueprint Medicines Corporation | 1 | $40 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Biocryst US Sales Co., LLC | 2 | $34 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Optinose US, Inc. | 1 | $23 |
| Organon | 7 | $22 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $17 |
| LEO Pharma Inc. | 1 | $15 |
| Coherus Oncology, Inc. | 1 | $14 |
| USWM, LLC | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,489 in reported general payments places this provider in the 75th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $97,209 |
| Dupixent PenDupilumab | 14 | $54,264 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $52,117 |
| XolairOmalizumab | 11 | $32,286 |
| Azelastine Hcl | 120 | $5,753 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,027 |
| Epinephrine | 11 | $2,077 |
| Fluticasone Propionate | 103 | $1,775 |
| Ipratropium Bromide | 30 | $1,652 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $558 |
| Montelukast Sodium | 14 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $843 | $97,20911 claims |
| GSKTrelegy Ellipta | $1,316 | $52,11736 claims |
| AstraZenecaSymbicort | $6,575 | $4,02716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Colorado Springs
- Christopher WebberColorado Springs$350K
- Eric CaplanColorado Springs$290K
- Robert NathanColorado Springs$130K
- Sterling KosmachColorado Springs$7K
- Deborah SweetColorado Springs$3K
- Rohit KatialDenver$758K
- Nicole BarberisLakewood$351K
- Jeffrey RumbyrtLakewood$348K
- Eileen WangDenver$274K
- Donald LeungDenver$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.